<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01549158</url>
  </required_header>
  <id_info>
    <org_study_id>P-110875-01</org_study_id>
    <nct_id>NCT01549158</nct_id>
  </id_info>
  <brief_title>Single Dose Study to Compare the Pharmacodynamics of Torasemide-PR 10 mg,Torasemide-IR 10 mg and Furosemide-IR 40 mg in Patients With Compensated Heart Failure</brief_title>
  <official_title>Randomized, Open-Label, Blinded-Endpoint, Crossover, Single Dose Study to Compare the Pharmacodynamics of Torasemide-PR 10 mg,Torasemide-IR 10 mg and Furosemide-IR 40 mg, in Patients With Compensated Heart Failure (CHF).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferrer Internacional S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferrer Internacional S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, blinded-endpoint, crossover, single dose study to compare&#xD;
      the pharmacodynamics of Torasemide-PR 10 mg, Torasemide-IR10 mg and furosemide-IR 40 mg. 30&#xD;
      patients of both sexes with CHF with a maximum imbalance of 60:40% in either direction will&#xD;
      be included in the study. Patients with compensated heart failure, grade II or III as defined&#xD;
      by the European Society of Cardiology, with a duration of ≥ 3 months at the time of inclusion&#xD;
      documented in the patient's record or patients who previously required diuretic therapy.&#xD;
&#xD;
      Principal variable will be the efficiency of sodium excretion that will be assessed as the&#xD;
      ratio between the average drug-induced natriuresis and the average drug recovered in urine&#xD;
      over 24 hours.&#xD;
&#xD;
      The difference between the efficiency of 24 hour sodium excretion following administration of&#xD;
      torasemide PR and furosemide will be formally tested by means of a Students t-test for paired&#xD;
      samples. The test will be two-sided at 5% significance level. Efficiency changes over time&#xD;
      will also be assessed, however will not be subject to formal statistical testing.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment&#xD;
  </why_stopped>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The efficiency of sodium excretion</measure>
    <time_frame>24 hours</time_frame>
    <description>Will be assessed as the ratio between the average drug-induced natriuresis and the average drug recovered in urine over 24 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic plasma parameters and pharmacokinetic urine parameters</measure>
    <time_frame>24 hours</time_frame>
    <description>Pharmacokinetic plasma parameters (Cmax, AUC0-t, AUC0-∞, t ½, Vd / F, Cl / F), pharmacokinetic urine parameters (ERFco , Ae24h, Ae ∞) and urine pharmacodynamic variables will be presented descriptively with no formal statistical testing.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Compensated Heart Failure</condition>
  <arm_group>
    <arm_group_label>Torasemide PR 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Furosemide-IR 40 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Torasemide-IR 10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>torasemide-PR</intervention_name>
    <description>Single oral dose of torasemide PR 10 mg</description>
    <arm_group_label>Torasemide PR 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide-IR</intervention_name>
    <description>Single oral dose of furosemide IR 40 mg</description>
    <arm_group_label>Furosemide-IR 40 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>torasemide-IR</intervention_name>
    <description>Single oral dose of torasemide IR 10 mg</description>
    <arm_group_label>Torasemide-IR 10 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to understand the nature of the study.&#xD;
&#xD;
          2. Obtain signed informed consent form approved by the Ethics Committee of the hospital&#xD;
             (CEIC).&#xD;
&#xD;
          3. Male and female, ≥ 18 years at the time of the informed consent signature.&#xD;
&#xD;
          4. Patients with compensated heart failure, grade II or III as defined by the European&#xD;
             Society of Cardiology, with a duration of ≥ 3 months at the time of inclusion&#xD;
             documented in the patient's record or patients who previously required diuretic&#xD;
             therapy.&#xD;
&#xD;
          5. Patients with stable heart failure on drug therapy. Stable drug therapy is defined as&#xD;
             not having introduced any new drug for heart failure within 4 weeks prior to&#xD;
             inclusion. Drugs doses could be adjusted during the study with the exception of the&#xD;
             diuretics&#xD;
&#xD;
          6. Lab analysis results, vital signs and ECG within normal ranges or not considered&#xD;
             clinically significant by the investigator.&#xD;
&#xD;
          7. For women only, the patient must be:&#xD;
&#xD;
               -  postmenopausal (≥ 1 year) or sterilized or,&#xD;
&#xD;
               -  without risk of becoming pregnant, not lactating, have a negative pregnancy test&#xD;
                  at study entry and without intention of becoming pregnant during the study course&#xD;
                  and use effective contraception.&#xD;
&#xD;
             Postmenopausal status is defined as 12 consecutive months of spontaneous amenorrhea or&#xD;
             confirmed by the results of follicle stimulating hormone (FSH) &gt; 40 mlU/mL or at least&#xD;
             6 months after oophorectomy (with or without hysterectomy) documented in the patients&#xD;
             record.&#xD;
&#xD;
          8. Body weight within the normal ranges (Quetelet's index between 19 and 30) expressed as&#xD;
             weight (kg) /height (m2).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hospitalization due to heart failure, acute coronary syndrome, myocardial infarction,&#xD;
             cardiac catheterization, revascularization, cardiac arrhythmia, transient ischemic&#xD;
             attack or stroke, cardiac arrhythmia within 6 weeks prior to inclusion or major&#xD;
             surgery including cardiac thoracic or within 8 weeks prior to inclusion.&#xD;
&#xD;
          2. Symptoms of angina at rest or with minimal activity (class III or IV, Canadian&#xD;
             Cardiovascular Society).&#xD;
&#xD;
          3. Severe aortic or mitral stenosis or clinically significant valvular heart disease that&#xD;
             can lead to surgery within 12 months after inclusion.&#xD;
&#xD;
          4. Hypertrophic obstructive cardiomyopathy, active myocarditis, constrictive pericarditis&#xD;
             or clinically significant congenital heart disease.&#xD;
&#xD;
          5. If ventricular assist devices, continuous inotropic therapy or hospitalization is&#xD;
             considered necessary in case of refractory end-stage heart failure.&#xD;
&#xD;
          6. Implementation of CRT within 3 months or cardioverter defibrillator in the 4 weeks&#xD;
             before inclusion.&#xD;
&#xD;
          7. High probability of receiving a heart transplant within 6 months after inclusion.&#xD;
&#xD;
          8. Main organ transplant (ex. lungs, liver, kidney, heart, bone).&#xD;
&#xD;
          9. Positive surface antigen of hepatitis B, hepatitis C or HIV or a known diagnosis of&#xD;
             AIDS.&#xD;
&#xD;
         10. Medical history or evidence of drug or alcohol abuse in the 3 months prior to&#xD;
             inclusion.&#xD;
&#xD;
         11. Concomitant cardiovascular disease that is expected to reduce life expectancy to less&#xD;
             than one year.&#xD;
&#xD;
         12. Scheduled routine iv infusions for heart failure (ex. inotropes, vasodilators,&#xD;
             diuretics) or routine ultrafiltration.&#xD;
&#xD;
         13. Digoxin therapy at steady state (approximately 6 hours post-dose) exceeding 1.0 ng/mL&#xD;
             at inclusion.&#xD;
&#xD;
         14. Chronic therapy with antiarrhythmic, antiepileptic drugs, eplerenone and&#xD;
             espironolactone except amiodarone and beta-blockers.&#xD;
&#xD;
         15. Current intake or within 14 days prior to inclusion of a potent inhibitor of CYP2C9&#xD;
&#xD;
         16. Current intake or within 28 days prior to inclusion of a potent inducer of CYP2C9.&#xD;
&#xD;
         17. Participation, in the 60 days or 5 half lives preceding the inclusion in the study, in&#xD;
             other clinical trial.&#xD;
&#xD;
         18. Systolic blood pressure &gt; 150mm Hg diastolic blood pressure &gt; 95 mmHg, confirmed on 2&#xD;
             separate visits before inclusion.&#xD;
&#xD;
         19. Heart rate in supine &gt; 100 beats/min after 5 minute rest or untreated symptomatic&#xD;
             bradycardia within one month prior to inclusion.&#xD;
&#xD;
         20. Total bilirubin &gt; 1.5 times ULN, or ALT or AST &gt; 3 times ULN.&#xD;
&#xD;
         21. Estimated GFR &gt; 30 ml/min/1.73 m2 calculated by the modification of diet in renal&#xD;
             disease (RD).&#xD;
&#xD;
         22. Chronic treatment with NSAIDs (&gt; 7 days), except aspirin &lt; 325 mg dose.&#xD;
&#xD;
         23. Uncontrolled insulin-dependent diabetes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre d'Investigació de Medicaments (CIM), Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>March 6, 2012</study_first_submitted>
  <study_first_submitted_qc>March 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2012</study_first_posted>
  <last_update_submitted>April 24, 2013</last_update_submitted>
  <last_update_submitted_qc>April 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>loop diuretics</keyword>
  <keyword>torasemide prolonged release</keyword>
  <keyword>torasemide immediate release</keyword>
  <keyword>Sutril Neo</keyword>
  <keyword>pharmacodynamic profile of Torasemide-PR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Torsemide</mesh_term>
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

